ArticleSurgical oncology insight2025
Outcomes following diagnostic laparoscopy in patients with peritoneal carcinomatosis deemed ineligible for cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC) due to disease burden.
Article in Surgical oncology insight, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Role of Palliative Cytoreductive Surgery for Patients with Incompletely Resectable Peritoneal Carcinomatosis from Lower Gastrointestinal Cancers.Annals of surgical oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Introduction: While cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) can improve overall survival (OS) for patients with peritoneal carcinomatosis from appendiceal or colorectal cancer, some patients are ineligible for CRS/HIPEC due to disease burden. This paper characterizes outcomes for patients who are evaluated by diagnostic laparoscopy (DL) and deemed ineligible for CRS/HIPEC. Methods: Medical records were retrospectively reviewed for patients who underwent DL and deemed ineligible for CRS/HIPEC (1/1/2009-1/1/2024). Date of death was confirmed using public obituaries. Treatment course/causes of death are summarized by descriptive statistics and OS by Kaplan-Meier analysis. Results: 124 patients were included. Median Peritoneal Cancer Index (PCI) score was 25. Median follow-up was 1.14 and median OS 1.29 years. 58 (46.8 %) died of their malignancy, 42 (33.9 %) died of unknown cause, and 24 (19.4 %) were alive at last follow-up. The most common causes of death were bowel obstruction (29, 23.4 %), multifactorial/failure to thrive (21, 16.9 %), and malignant ascites (15, 12.1 %). Patients who underwent some form of additional therapy after DL (1.43 versus 0.48 years, p < 0.001) or who enrolled in a clinical trial (1.91 versus 1.21 years, p = 0.030) had prolonged OS. Conclusions: OS for patients with peritoneal carcinomatosis from appendiceal or colorectal cancer who are deemed ineligible for CRS/HIPEC after DL is 1.29 years without significant variation by primary pathology, PCI, peritoneal cytology, or presence of hematogenous metastases. Patients who get some form of additional therapy following their DL have prolonged OS. The most common causes of death are bowel obstruction, failure to thrive, and malignant ascites.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.